|
RFC5 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 9.85530546060431E-11 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.1072999994699E-07 |
| Normal-vs-Stage2 |
5.975000E-03 |
| Normal-vs-Stage3 |
1.54472999999156E-05 |
| Normal-vs-Stage4 |
7.58690000000062E-05 |
| Stage1-vs-Stage2 |
8.414800E-01 |
| Stage1-vs-Stage3 |
6.686400E-01 |
| Stage1-vs-Stage4 |
5.602400E-02 |
| Stage2-vs-Stage3 |
6.272200E-01 |
| Stage2-vs-Stage4 |
7.539900E-02 |
| Stage3-vs-Stage4 |
1.143590E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.09500000178286E-08 |
| Normal-vs-AfricanAmerican |
6.045500E-04 |
| Normal-vs-Asian |
1.026160E-02 |
| Caucasian-vs-AfricanAmerican |
4.088400E-02 |
| Caucasian-vs-Asian |
4.497200E-01 |
| AfricanAmerican-vs-Asian |
2.126300E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
4.27049999995877E-06 |
| Normal-vs-Female |
6.8265004760093E-10 |
| Male-vs-Female |
8.477800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
8.38830000016166E-07 |
| Normal-vs-Age(41-60Yrs) |
3.82340000004699E-06 |
| Normal-vs-Age(61-80Yrs) |
4.16989998086592E-09 |
| Normal-vs-Age(81-100Yrs) |
3.440000E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
9.646200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
7.641600E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.227000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.954400E-02 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
1.268960E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.251800E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
9.118100E-02 |
| Classical-VS-Follicular |
1.600190E-01 |
| Classical-VS-Other |
1.824770E-01 |
| Classical-VS-Normal |
1.59009999611825E-08 |
| Tall-VS-Follicular |
5.020400E-01 |
| Tall-VS-Other |
9.745200E-01 |
| Tall-VS-Normal |
8.235500E-04 |
| Follicular-VS-Other |
6.849400E-01 |
| Follicular-VS-Normal |
4.00959999999895E-05 |
| Other-VS-Normal |
4.582000E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.3519999999545E-06 |
| Normal-vs-N1 |
3.971600E-04 |
| N0-vs-N1 |
6.330400E-01 |
|
|
